idiopathic pulmonary fibrosis

News

Brainomix AI lends weight to Endeavor Bio's IPF trial data

An AI-based imaging tool from Brainomix has been used to enrich data from a phase 2a trial of Endeavor's idiopathic pulmonary fibrosis drug taladegib.

News

UK first in Europe to clear Boehringer's IPF drug Jascayd

Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.

News

Pulmonary fibrosis drug developer Avalyn files IPO

Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.

News

Insilico ends 2025 with $293m Hong Kong IPO

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

News

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

News

PureTech launches lung disease specialist Celea

PureTech launches Celea Therapeutics, tasked with bringing forward a drug that could offer a 'step change' in pulmonary fibrosis treatment.

Brainomix AI lends weight to Endeavor Bio's IPF trial data

UK first in Europe to clear Boehringer's IPF drug Jascayd

Pulmonary fibrosis drug developer Avalyn files IPO

Insilico ends 2025 with $293m Hong Kong IPO

Boehringer bags FDA okay for new pulmonary fibrosis drug

PureTech launches lung disease specialist Celea

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

idiopathic pulmonary fibrosis

Editor's Picks